A Randomised, Double-blind, Placebo-Controlled, Dose-ranging, Parallel Design Study to Evaluate the Efficacy and Safety of the Endothelin Antagonist Avosentan in Patients With Diabetic Kidney Disease.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Avosentan (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 08 Aug 2011 New trial record
- 10 May 2011 This trial is completed in Belgium and has prematurely ended in Hungary, Latvia, Germany, Czech Republic.